Search hospitals > Nebraska > Omaha
Creighton University Medical Center
Claim this profileOmaha, Nebraska 68131
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
368 reported clinical trials
3 medical researchers
Summary
Creighton University Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Creighton University Medical Center is involved with conducting 368 clinical trials across 503 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
170 reported clinical trials
235 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
100 reported clinical trials
168 drugs studied
Mehmet S. CopurRocky Mountain Cancer Centers-Thornton12 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Serous Adenocarcinoma
2 reported clinical trials
8 drugs studied
Clinical Trials running at Creighton University Medical Center
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Pancreatic Cancer
Multiple Myeloma
Adenocarcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Creighton University Medical Center?
Creighton University Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Creighton University Medical Center is involved with conducting 368 clinical trials across 503 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.
Where is Creighton University Medical Center located?
To reach Creighton University Medical Center in Omaha, NE, take I-680 to exit 4 for Mercy Road, then head north for about a mile to the hospital located at 7500 Mercy Rd.
Who should I call to ask about financial aid or insurance network?
**Creighton University Medical Center Financial Assistance:**
- **Contact Information:** For financial assistance, reach out to the Financial Aid Office via email at finaid@creighton.edu or call 800.282.5835 / 402.280.2731. They assist with undergraduate, graduate, or professional school financial inquiries. For specific staff contacts, visit the Creighton University website.
**Insurance-Related Inquiries:**
- **Contact Information:** For insurance questions, waivers, or enrollment in the University-sponsored Student Health Insurance Plan, contact the Student Health Education and Compliance Office at studentinsurance@creighton.edu or call 402.280.2735.
What insurance does Creighton University Medical Center accept?
The Creighton University Medical Center accepts UnitedHealthcare Student Resources and UnitedHealthcare medical coverage. Students can benefit from the university-sponsored Student Health Insurance Plan, offering comprehensive medical and mental health care. Employees have three plan options: Creighton Consumer Account Plan (CCAP), PPO1, and PPO2, with pharmacy benefits by Express Scripts, dental by MetLife, and vision by Vision Service Plan (VSP).
What awards or recognition has Creighton University Medical Center received?
Creighton University Medical Center, located in Omaha, Nebraska, is celebrated for its high-quality care, as recognized by U.S. News. The university's Division of Clinical Research enhances clinical studies by assisting in various stages including IRB submission and study management. Its research excellence spans cancer, antibiotic development, diabetes, and hearing, with significant accomplishments in hereditary and skin cancer, breast and prostate cancer, and hearing loss prevention.